Phase I Trial of ISIS 104838, a 2′-Methoxyethyl Modified Antisense Oligonucleotide Targeting Tumor Necrosis Factor-α

K. Lea Sewell, Richard S. Geary, Brenda F. Baker, Josephine Glover, Timothy Mant, Rosie Z. Yu, Joseph A. Tami, F. Andrew Dorr

Journal of Pharmacology and Experimental Therapeutics · 2002 · 120 citations · 30 references

References

30